KPV

Name: KPV
Availability: InStock

5mg vial

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). It retains the potent anti-inflammatory activity of the parent hormone without its pigmentation or appetite effects, and is studied across inflammatory bowel disease, dermatological inflammation, mast-cell modulation and wound healing.

Select size

Checking availability…

Researched for

Broad anti-inflammatory activity via NF-κB suppression
Improved outcomes in IBD and colitis animal models
Reduced inflammatory dermatological lesions in research
Mast-cell stabilisation relevant to allergic and MCAS research
Antimicrobial activity against several common pathogens
Favourable tolerability with minimal reported side effects

Mechanism of action

Enters cells and translocates to the nucleus to inhibit NF-κB activation, suppressing downstream pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). Also stabilises mast cells and modulates innate immune responses.

Research protocol

Common research protocols use 200–500mcg subcutaneously once daily, or higher oral/encapsulated doses (approx. 500mcg–1mg) for gut-targeted protocols. Cycles typically run 4–8 weeks.

Half-life

Plasma half-life is short (approx. 30–60 minutes); local tissue effects persist longer.

Reconstitution

Reconstitute a 10mg vial with 2–4mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently.

Storage

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.

Research considerations

• Human RCT data remains limited; most evidence is preclinical or early-phase.
• Oral bioavailability is modest - encapsulation or compounding is typically required for gut-targeted use.
• Long-term safety dataset is not yet well characterised.